Haemonetics Corp
HAE
View Detailed Chart
59.340USD
-5.680-8.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.77BMarket Cap
16.30P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-8.74%
5 Days
-10.98%
1 Month
-28.31%
6 Months
-21.68%
Year to Date
-25.96%
1 Year
-5.79%
View Detailed Chart
TradingKey Stock Score of Haemonetics Corp
Currency: USD Updated: 2026-02-06Key Insights
Haemonetics Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 88.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haemonetics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Haemonetics Corp Highlights
StrengthsRisks
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.36B.
Undervalued
The company’s latest PE is 16.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.33M shares, decreasing 14.59% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 22.93K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.27.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
88.000
Target Price
+35.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Haemonetics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Haemonetics Corp Info
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Ticker SymbolHAE
CompanyHaemonetics Corp
CEOSimon (Christopher A)
Websitehttps://www.haemonetics.com
Related Instruments
+3.02%
+0.09%
+1.60%
+2.48%
+0.40%
-1.14%
-0.05%
-2.35%
-1.76%
+2.65%
+2.64%
+2.03%
+2.01%
+2.38%
+1.70%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70819.990
+849.860 (+1.21%)
282.580
+22.390 (+8.61%)
2077.100
+25.370 (+1.24%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
